NasdaqGM - Nasdaq Real Time Price USD

Ligand Pharmaceuticals Incorporated (LGND)

Compare
103.44 -2.36 (-2.23%)
As of 11:34 AM EDT. Market Open.
Loading Chart for LGND
DELL
  • Previous Close 105.80
  • Open 105.08
  • Bid 103.10 x 100
  • Ask 103.72 x 100
  • Day's Range 103.01 - 106.41
  • 52 Week Range 49.24 - 112.13
  • Volume 18,353
  • Avg. Volume 127,590
  • Market Cap (intraday) 1.89B
  • Beta (5Y Monthly) 0.91
  • PE Ratio (TTM) 44.39
  • EPS (TTM) 2.33
  • Earnings Date Nov 6, 2024 - Nov 11, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date Jul 2, 2010
  • 1y Target Est 124.00

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.

www.ligand.com

58

Full Time Employees

December 31

Fiscal Year Ends

Recent News: LGND

View More

Performance Overview: LGND

Trailing total returns as of 9/3/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

LGND
44.83%
S&P 500
16.91%

1-Year Return

LGND
55.46%
S&P 500
23.49%

3-Year Return

LGND
18.58%
S&P 500
22.91%

5-Year Return

LGND
82.39%
S&P 500
90.55%

Compare To: LGND

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: LGND

View More

Valuation Measures

Annual
As of 8/30/2024
  • Market Cap

    1.94B

  • Enterprise Value

    1.72B

  • Trailing P/E

    45.41

  • Forward P/E

    25.32

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    14.25

  • Price/Book (mrq)

    2.49

  • Enterprise Value/Revenue

    12.84

  • Enterprise Value/EBITDA

    19.29

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    31.57%

  • Return on Assets (ttm)

    0.61%

  • Return on Equity (ttm)

    5.85%

  • Revenue (ttm)

    133.48M

  • Net Income Avi to Common (ttm)

    42.14M

  • Diluted EPS (ttm)

    2.33

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    226.93M

  • Total Debt/Equity (mrq)

    0.99%

  • Levered Free Cash Flow (ttm)

    -18.11M

Research Analysis: LGND

View More

Company Insights: LGND

Research Reports: LGND

View More

People Also Watch